NEWRON PHARMACEUTICALS SPA (NP5.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:NP5 - IT0004147952 - Common Stock
19.42 EUR
-0.54 (-2.71%)
Taking everything into account, NP5 scores 5 out of 10 in our fundamental rating. NP5 was compared to 54 industry peers in the Pharmaceuticals industry. NP5 has an average financial health and profitability rating. NP5 shows excellent growth, but is valued quite expensive already. This makes NP5 very considerable for growth investing!
1. Profitability
1.1 Basic Checks
NP5 had positive earnings in the past year.
NP5 had a negative operating cash flow in the past year.
NP5 had negative earnings in 4 of the past 5 years.
In the past 5 years NP5 always reported negative operating cash flow.
1.2 Ratios
NP5 has a better Return On Assets (24.79%) than 100.00% of its industry peers.
With an excellent Return On Equity value of 1086.63%, NP5 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
NP5's Return On Invested Capital of 47.97% is amongst the best of the industry. NP5 outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.79% | ||
| ROE | 1086.63% | ||
| ROIC | 47.97% |
ROA(3y)-28.32%
ROA(5y)-31.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of NP5 (30.83%) is better than 94.44% of its industry peers.
The Operating Margin of NP5 (50.93%) is better than 100.00% of its industry peers.
NP5 has a better Gross Margin (98.26%) than 100.00% of its industry peers.
In the last couple of years the Gross Margin of NP5 has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 50.93% | ||
| PM (TTM) | 30.83% | ||
| GM | 98.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y4.26%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NP5 is creating value.
Compared to 1 year ago, NP5 has more shares outstanding
The number of shares outstanding for NP5 has been increased compared to 5 years ago.
NP5 has a better debt/assets ratio than last year.
2.2 Solvency
NP5 has an Altman-Z score of 7.17. This indicates that NP5 is financially healthy and has little risk of bankruptcy at the moment.
NP5's Altman-Z score of 7.17 is amongst the best of the industry. NP5 outperforms 92.59% of its industry peers.
A Debt/Equity ratio of 25.32 is on the high side and indicates that NP5 has dependencies on debt financing.
The Debt to Equity ratio of NP5 (25.32) is worse than 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 25.32 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.17 |
ROIC/WACC6.4
WACC7.49%
2.3 Liquidity
NP5 has a Current Ratio of 2.60. This indicates that NP5 is financially healthy and has no problem in meeting its short term obligations.
NP5 has a better Current ratio (2.60) than 83.33% of its industry peers.
A Quick Ratio of 2.60 indicates that NP5 has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.60, NP5 belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.6 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 232.04% over the past year.
The Revenue has grown by 467.41% in the past year. This is a very strong growth!
Measured over the past years, NP5 shows a very strong growth in Revenue. The Revenue has been growing by 48.83% on average per year.
EPS 1Y (TTM)232.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)467.41%
Revenue growth 3Y107.38%
Revenue growth 5Y48.83%
Sales Q2Q%249.22%
3.2 Future
Based on estimates for the next years, NP5 will show a very strong growth in Earnings Per Share. The EPS will grow by 45.40% on average per year.
NP5 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.10% yearly.
EPS Next Y-231.2%
EPS Next 2Y-84.82%
EPS Next 3Y-35.68%
EPS Next 5Y45.4%
Revenue Next Year-67.36%
Revenue Next 2Y-49.49%
Revenue Next 3Y-35.39%
Revenue Next 5Y32.1%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 14.28, NP5 is valued correctly.
NP5's Price/Earnings ratio is a bit cheaper when compared to the industry. NP5 is cheaper than 70.37% of the companies in the same industry.
NP5's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.49.
NP5 is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.28 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NP5 is valued a bit more expensive than the industry average as 61.11% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 16.13 |
4.3 Compensation for Growth
NP5 has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as NP5's earnings are expected to decrease with -35.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.82%
EPS Next 3Y-35.68%
5. Dividend
5.1 Amount
No dividends for NP5!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:NP5 (12/5/2025, 7:00:00 PM)
19.42
-0.54 (-2.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners11.1%
Inst Owner ChangeN/A
Ins Owners10.76%
Ins Owner ChangeN/A
Market Cap387.62M
Revenue(TTM)51.39M
Net Income(TTM)15.84M
Analysts85
Price Target20.09 (3.45%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.87%
PT rev (3m)12.06%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)33.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)28.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.28 | ||
| Fwd PE | N/A | ||
| P/S | 7.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 265.86 | ||
| P/tB | 265.86 | ||
| EV/EBITDA | 16.13 |
EPS(TTM)1.36
EY7%
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS2.57
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.79% | ||
| ROE | 1086.63% | ||
| ROCE | 64.78% | ||
| ROIC | 47.97% | ||
| ROICexc | 63.39% | ||
| ROICexgc | 63.39% | ||
| OM | 50.93% | ||
| PM (TTM) | 30.83% | ||
| GM | 98.26% | ||
| FCFM | N/A |
ROA(3y)-28.32%
ROA(5y)-31.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y4.26%
F-Score6
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 25.32 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.4 | ||
| Cap/Depr | 6.77% | ||
| Cap/Sales | 0.03% | ||
| Interest Coverage | 13.81 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.6 | ||
| Altman-Z | 7.17 |
F-Score6
WACC7.49%
ROIC/WACC6.4
Cap/Depr(3y)7.05%
Cap/Depr(5y)9.34%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)232.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-231.2%
EPS Next 2Y-84.82%
EPS Next 3Y-35.68%
EPS Next 5Y45.4%
Revenue 1Y (TTM)467.41%
Revenue growth 3Y107.38%
Revenue growth 5Y48.83%
Sales Q2Q%249.22%
Revenue Next Year-67.36%
Revenue Next 2Y-49.49%
Revenue Next 3Y-35.39%
Revenue Next 5Y32.1%
EBIT growth 1Y325.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-151.15%
EBIT Next 3Y-30.19%
EBIT Next 5Y38.05%
FCF growth 1Y-73.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.71%
OCF growth 3YN/A
OCF growth 5YN/A
NEWRON PHARMACEUTICALS SPA / NP5.DE FAQ
Can you provide the ChartMill fundamental rating for NEWRON PHARMACEUTICALS SPA?
ChartMill assigns a fundamental rating of 5 / 10 to NP5.DE.
Can you provide the valuation status for NEWRON PHARMACEUTICALS SPA?
ChartMill assigns a valuation rating of 2 / 10 to NEWRON PHARMACEUTICALS SPA (NP5.DE). This can be considered as Overvalued.
How profitable is NEWRON PHARMACEUTICALS SPA (NP5.DE) stock?
NEWRON PHARMACEUTICALS SPA (NP5.DE) has a profitability rating of 6 / 10.
What is the expected EPS growth for NEWRON PHARMACEUTICALS SPA (NP5.DE) stock?
The Earnings per Share (EPS) of NEWRON PHARMACEUTICALS SPA (NP5.DE) is expected to decline by -231.2% in the next year.